Author: IQ TIMES MEDIA
March 4 (Reuters) – PepGen said on Wednesday that the U.S. Food and Drug Administration has placed a partial clinical hold on its mid‑stage trial of a rare muscle disease drug, sending its shares plunging over 25% in extended trading. The drug, PGN‑EDODM1, is being tested for myotonic dystrophy type 1, a genetic disease that causes muscles to weaken and tighten over time, making movement and daily activities harder. PepGen said the health regulator’s concerns relate to earlier laboratory and animal studies the company submitted. The agency did not flag any safety concerns from patient data generated in an early-stage…
March 5 (Reuters) – Eli Lilly said on Thursday it had rolled out a platform to help employers connect with organizations offering low-cost benefits and comprehensive obesity-care programs, aiming to widen access to its blockbuster weight-loss drug, Zepbound. Through Lilly Employer Connect platform, its multi-doseweight-loss drug device Zepbound KwikPen will be available tonetwork pharmacies at a discounted price of $449 for all doses. The program provides employees access to weight-lossmedicines at lower out-of-pocket costs, and gives employers greater cost predictability and transparency “By enabling coverage outside traditional benefit designs,we lower barriers to treatment and give employers greatercontrol over how they…
March 5 (Reuters) – CVS Health will launch an AI-enabled platform in partnership with Alphabet’s Google Cloud unit that will bring together data from diverse sources to help customers manage their health in real time, they said on Thursday. Health100 will be an integrated health care engagement platform for customers, regardless of the pharmacy or insurer they use. The initial launch of Health100 will be in 2026, with details expected to be revealed at The Check Up, Google’s annual health event later in March. * The Health100 will use built-in agentic AI – which needsminimal human intervention – to provide…
SHANGHAI, March 6 (Reuters) – China has approved Pfizer’s GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions in coming years.The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk, Eli Lilly, and Innovent Biologics. “This marks a breakthrough in field of weight management,” Sciwind Biosciences, from which Pfizer licensed mainland China commercialisation rights in February, said on its website. Sales of Novo’s Wegovy on Alibaba’s Tmall e-commerce platform…
By Christy Santhosh March 6 (Reuters) – French drugmaker Servier said on Friday it would buy U.S.-based Day One Biopharmaceuticals for about $2.5 billion, expanding its brain tumor treatment portfolio. Servier has offered $21.50 per share in cash, a premium of 68% to the stock’s last close. Shares of Day One jumped 65% in morning trade. The deal will give the company access to Day One’s Ojemda, the only U.S. Food and Drug Administration-approved monotherapy for pediatric low-grade glioma, the most common form of brain tumor in children. Servier already sells adult glioma drug Voranigo and the deal strengthens its…
It’s official: Elon Musk is combining SpaceX and xAI as he overhauls his sprawling business empire.Musk told workers in a Monday memo that SpaceX has acquired xAI, his AI company, sources familiar with the matter confirmed to Business Insider.The CEO wrote that the deal would create “the most ambitious, vertically-integrated innovation engine on (and off) Earth, with AI, rockets, space-based internet, direct-to-mobile device communications and the world’s foremost real-time information and free speech platform.”SpaceX, which Musk founded in 2002, is reportedly gearing up for an initial public offering this year that could value the Starship maker at $1.5 trillion.In the…
Moltbook, a new Reddit-style social network made entirely for AI agents, can be read in a few different ways.It might be an ominous glimpse of an AI-driven future. Or a clever meta-commentary on how humans behave online. Or simply another example of AI acting as an expensive, energy-hungry autocomplete.Which interpretation you land on depends on where you fall in the ongoing debate about artificial intelligence.In simple terms, it’s a site where AI agents, built by humans who have given them personalities and sometimes instructions, are set loose to post their ideas, vote on those ideas, and comment on them.One of…
At an Amazon Fresh store in New York, some customers would walk in and ask employees: Do you have products from Amazon’s other grocery store here?”I would run into people looking for a specific product from Whole Foods,” one employee at the store told Business Insider.Amazon opened Fresh in 2020 after acquiring Whole Foods in 2017. Some assumed that Amazon Fresh would offer their favorite organic yogurt or premium meat because of the shared ownership. While Fresh stores did stock some Whole Foods 365 products, store employees said, Amazon sought to offer more affordable groceries and showcase its technology, such…
OpenAI is paying a price for its rushed deal with the Pentagon. Loading audio narration… On Saturday, Anthropic’s Claude dethroned ChatGPT to take the top spot in the US Apple App Store. Data obtained by Business Insider shows just how suddenly the tide turned in the fight for app downloads.Data from Appfigures, an app intelligence firm, showed that Claude surpassed ChatGPT in the US for the first time on Saturday. Claude’s US downloads were up 240% month-over-month in February, Appfigures estimated, to 1.1 million more than the previous month.Claude is now the No. 1 free iPhone app in five markets:…
2025-09-29T21:34:56Z Share Facebook Email X LinkedIn Reddit Bluesky WhatsApp Copy link lighning bolt icon An icon in the shape of a lightning bolt. Impact Link Save Saved Read in app This story is available exclusively to Business Insider subscribers. Become an Insider and start reading now. Have an account? Log in. Donald Trump and Alphabet reached an agreement in his lawsuit against YouTube. Alphabet, which owns YouTube, will pay a total of $24.5 million to settle the post-January 6-related case. Trump has directed that part of his money will finance the construction of the White House ballroom. Alphabet is the…